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Abstract 
 Left ventricular hypertrophy (LVH) was one of the earliest studied echocardiographic 
characteristics of the left ventricle. As the myriad of measurable metrics has multiplied over 
recent years, this reliable and relevant variable can often be overlooked. In this paper, we 
discuss appropriate techniques for accurate analysis, underlying pathophysiology, and the 
contributions from various risk factors. The prognostic implications of LVH on stroke, serious 
arrhythmias, and sudden cardiac death are reviewed. Finally, we examine the effect of therapy 
to reduce LVH and the resultant clinical outcomes. 
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Abbreviations: 
ACE - angiotensin converting enzyme 
AF - atrial fibrillation 
Ang II - angiotensin II 
ARB - angiotensin receptor blocker 
ASE - American Society of Echocardiography 
BMI - body mass index 
BP - blood pressure 
BSA - body surface area 
CAD - coronary artery disease 
CCBs - calcium channel blockers 
CI - confidence interval 
CKD - chronic kidney disease 
CMR – cardiovascular magnetic resonance 
CR - concentric remodeling 
CV – cardiovascular  
CVD – cardiovascular disease 
DBP – diastolic blood pressure 
DM - diabetes mellitus 
EACVI - European Association of Cardiovascular Imaging 
Echo – echocardiography 
ET-1 - endothelin-1 
FHS – Framingham Heart Study 
HF - heart failure 
HTN - hypertension 
HR - hazard ratio 
LV - left ventricle 
LVEF – left ventricular ejection fraction 
LVH – left ventricular hypertrophy 
LVM – left ventricular mass 
MI – Myocardial Infarction 
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MMPs - matrix-metalloproteinases 
OR - odds ratio 
OSA - obstructive sleep apnea 
RWT - relative wall thickness 
RV - right ventricle 
SBP - systolic blood pressure 
SCD - sudden cardiac death 
T-tubule - transverse-tubule  
TGF-B1 - tissue growth factor-B1 
TIMPs - tissue inhibitors of metalloproteinases 
VEA - ventricular ectopic activity 
 
Introduction 
The left ventricle (LV) of the human heart can increase in size and undergo geometric 
changes in response to a wide array of pathophysiological stressors. These morphological 
transformations often closely follow disease progression, and provide valuable prognostic 
information about clinical outcomes. As such the study of LV hypertrophy (LVH) and its 
associated disease processes, implications, and treatments is of tremendous value. LVH and 
remodeling can be easily measured using a variety of non-invasive techniques, chief of among 
these being echocardiography. In this review, we discuss the current state of quantification of 
LVH, broad pathophysiology, associated disease states, prognosis, and effect of treatment.  
 
LV Mass (LVM) Quantification and Definition 
 LVH was first studied non-invasively with electrocardiography and angiography, but with 
growth of echocardiography (echo) in the 1970s this quickly became the preferred technique.1 
The earliest echo studies recognized the value of this modality in accurately measuring wall 
thickness, end-diastolic diameter, and septal to posterior wall ratios to differentiate between 
types of LVH.2 Devereux and Reichek conducted the first anatomic validation of LVM by echo in 
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1977 when they compared values on 34 patients with post-mortem LVM.3 The original ellipsoid 
model they developed was based on short axis linear measurements taken of the LV from 
parasternal views using M-mode echo. They further refined this method in the 1980s with post-
mortem analyses, and a variation of the cube formula they developed (LVM = 0.8 {1.04[(LVIDd + 
PW + IVSd)3 (LVIDd)3]} + 0.6 g) is still in use today.4,5 With the improvement of 2D echo in the 
1980s, these images were first used to ensure accurate linear measurement but then also to 
develop new models. The area-length and truncated ellipsoid formulas are 2D techniques based 
on tracings of the LV in short axis and length parameters from apical views.6 These formulas are 
significantly more complicated but also validated against autopsy data.5,7 The main benefit to a 
2D LV quantification is improved accuracy in the setting of abnormal LV geometry, however,  
this method is subject to other errors such as LV foreshortening.6 Despite these newer 
techniques, there has been a tremendous amount of prognostic data published about LVM 
calculated with linear measurements, giving intrinsic value to comparison by this method.8,9 
The most recent American Society of chocardiography (ASE)/European Association of 
Cardiovascular Imaging (EACVI) guidelines recommend either technique for LVM quantification 
in a normal shaped LV.10 The significance of technique becomes apparent, as the upper limit of 
normal for LVM varies based on the method of quantification; 95g/m2 and 115g/m2 for women 
and men respectively using a linear measurement, versus 88g/m2 and 102g/m2 using a 2D 
measurement.10 The newest 3D techniques measure LVM directly without relying upon a 
model, accounting for abnormal LV geometry without the pitfalls or foreshortening.11 Normal 
values for 3D have been published, however, given the lack of long-term prognostic information 
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and the evolution with changing technology, this is not yet the recommended first line 
technique for LV quantification.10  
 An important consideration in the quantification of LVM is appropriate indexing. LVM is 
known to increase with height and weight, thus reference values must be normalized to these 
variables in order to define a threshold for any particular individual’s body size. Currently the 
ASE/EACVI recommend indexing LVM to body surface area (BSA) in m2, a calculated value which 
includes a patient’s weight and height.10,12 Controversy arises when considering what degree of 
LVH is physiologic vs. pathologic for obese individuals, and alternative indexing has been 
proposed. De Simone et al. evaluated 611 normotensive individuals and found LVM was related 
to height to the 2.7 power and BSA to the 1.5 power. They also found that 14% of obese 
individuals with normal LVM by BSA had LVH when LVM was indexed to height2.7.13 A later 
study of 2400 patients, including those with hypertension (HTN), found a prevalence of LVH at 
20-28% when indexed to height2.7 vs. 7-11% when indexed to BSA. The population attributable 
risk of cardiovascular (CV) disease (CVD) was 1.8 times greater in the group indexed to height 
alone.14 A review of 7,528 patients combined from the Askleipos study and the Multiethnic 
Study of Atherosclerosis found that indexing LVM to height1.7 fared better at predicting CVD 
events than indexes of height2.7 or BSA.15 All these results suggest but do not definitively 
demonstrate that some pathologic LVH is underestimated in obese patients indexed with BSA.  
 Similar to the concerns with the evolution of 3D imaging technology and comparator 
validity, 2D echocardiography has changed significantly in the past 20 years. Harmonic imaging 
was developed for echo in the late 1990s, which took advantage of the acoustic properties of 
ultrasound waves to emit a low frequency signal for better tissue penetration and then receive 
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a reflected signal at a higher harmonic frequency for better resolution.16 In a study from 2003 in 
30 patients, the average measured LVM was 26% greater with harmonic versus fundamental 
imaging.17 In vitro analysis with porcine hearts showed that harmonic imaging over measures 
tissue wall thickness and under measures LV internal diameters.18 Another small study from 
2002 reported larger LVM measurements with harmonic imaging (93+/-25g/m2 vs. 79g/m2, 
p<0.001), results mirrored in a study from the same year of 50 patients showing significant 
differences in LVM with harmonic imaging (185+/-74g vs. 166 +/-68g p<0.0001).19,20 As 
improved techniques for LVM quantification such as 3D become more readily available these 
differences will be less significant, but as long as linear measurements are used for prognostic 
comparison the differences in technique should be noted.21 
 
Pathophysiology 
LVH as a singular clinical entity encompasses a broad group of diagnoses and 
pathologies, including infiltrative, hypertrophic, and familial dilated cardiomyopathies. From a 
population standpoint, however, the vast majority of LVH is related to chronic pressure and 
volume overload, as well as ischemic disease, with the caveat that other common comorbidities 
may play a synergistic and potentially independent role. The complicated role of hemodynamics 
in LVH was explored by Ganau et al. in 100 patients with and without HTN. They found that LV 
wall thickness and mass increased with blood pressure (BP) as expected, but statistically 
followed end diastolic volume more closely. This implies that stroke work, a combination of BP 
and stroke volume, was a better predictor of the compensatory increase in size than BP alone.22 
An increase in LV size, both by an increase in wall thickness and an overall increase in LV 
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diameter, is thought to be an adaptive response to increase in hemodynamic stressors; 
increased myocardial mass works to decrease wall strain and allow the myocyte to function at 
its prior level. Traditionally an increase in LV end diastolic diameter was thought to be a result 
of increased volume, such as in mitral regurgitation, and an increase in LV thickness was the 
result of increased afterload as with aortic stenosis. Recently, however , this has been called 
into question, as large studies have shown the correlation between BP and LVM to only account 
for a fraction of the variability.23,24 In closely controlled animal studies with aortic banding,  
there is significant heterogeneity of LVH in response to an identical increase in hemodynamic 
stress.25  
 There appears to be a genetic component, as LVH was shown to have the highest 
correlation among first degree relatives in the Framingham Heart Study (FHS), and also shown 
to be linked in twin studies.26,27 Specific genes and polymorphisms have been identified which 
are associated with LVH among siblings and in large population studies, giving weight to the 
heritability argument.28,29 
 At the cellular level, a hallmark of LVH is fibrosis and an alteration of the extracellular 
matrix. In several human studies of HTN and LVH, transvenous endomyocardial biopsies have 
found increased myocardial collagen in comparison with normotensive patients.30,31 This 
collagen has further been associated with progressive systolic dysfunction. Collagen deposits in 
two distinct places in the HTN heart – both around the vessels, in what is termed perivascular 
fibrosis, and in the interstitial space, known as the endomysium and perimysium.32 This 
collagen is deposited by myofibroblasts – termed as such because they exist within the muscle 
cells but deposit collagen similar to fibroblasts. They are morphologically distinct from 
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fibroblasts, however, and this transformation from fibroblast to myofibroblast is mediated by 
Angiotensin II (Ang II), Endothelin-1 (ET-1) and Tissue growth Factor-B1 (TGF-B1).33 Ang II 
appears to play a central role, as it is secreted by activated macrophages in the setting of 
apoptosis and hemodynamic distress. The myofibroblasts which develop as a result of these 
increased cytokines alter the extra-cellular matrix and upregulate matrix-metalloproteinases 
(MMPs) and down-regulate tissue inhibitors of metalloproteinases (TIMPs). This MMP/TIMP 
imbalance has been extensively implicated in fibrosis and development of heart failure (HF).34 
Many of these changes have been considered a necessary adaptive response to increased 
hemodynamic load to prevent myocardial collapse, but MMP-deficient animal models have 
shown decreased hypertrophy and decreased fibrosis in response to sustained afterload 
without hemodynamic collapse.35 MMP inhibitors have also been shown to prevent the onset 
of HF in spontaneously hypertensive rats.36  
 Giving further weight to the argument for a maladaptive neurohormonal milieu 
independent of hemodynamic stress, LVH in humans has been associated with increased 
circulating angiotensin II, epinephrine, and aldosterone, independent of BP.37 Increased 
hormones, such as aldosterone from adipose tissue in metabolic syndrome have been 
associated with LVH in obesity.38 A systemic response can be argued when chambers that are 
not directly affected by hemodynamic stressors, such as the right ventricle (RV), have been 
found to be hypertrophied in spontaneously hypertensive rats.39 Correspondingly treatment 
with aldosterone receptor antagonists, such as eplerenone , has been shown to reduce RV 
fibrosis in spontaneously hypertensive rats without significant effect on BP.40 Treatment with 
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losartan, an angiotensin receptor blocker (ARB), has also been associated with decreased 
myocardial fibrosis in humans with HTN.31  
 Another theme in the pathophysiology of LVH is progressive structural disorganization. 
At the cellular level, as there is increased collagen turnover driven by myofibroblasts, the hastily 
deposited collagen is laid down in an orthogonal meshwork. This disarrayed collagen 
architecture is associated with systolic and diastolic dysfunction.41 At the ultrastructural level 
there has been a recent investigation of the transverse-tubule (t-tubule) in the progression of 
LVH. The t-tubule system is an organized series of membranes which function to conduct the 
membrane depolarization rapidly to many myocytes simultaneously for a coordinated 
myocardial contraction.42 Wei et al. showed in 2010 a gradual disorganization of t-tubule 
architecture in a rat model of LVH.43 Subsequent studies showed these changes in t-tubule 
disorganization were associated with strain abnormalities, and even preceded fibrosis or 
systolic dysfunction.44 T-tubule ultrastructural remodeling has been shown to correlate down to 
a regional level of dysfunction.45 In a recent analysis of myocardial specimens taken during LV 
assist device placement, a novel sheet-like remodeling of the t-tubule system was described, 
which predicted functional recovery after LV unloading.46 All this is notable as there are several 
anchoring proteins between t-tubules and sarcolemma which could be target for potential 
therapy.47 
 Another issue in LVH is impaired coronary flow reserve. As the LV thickens, both as 
product of the perivascular collagen deposition and due to increased wall thickness, the 
minimum coronary vascular resistance increases and thus the maximum coronary flow reserve 
decreases.48,49 This means that in the setting of exertion, decreased coronary flow reserve leads 
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to sub-endocardial ischemia, which could be associated with diastolic dysfunction as well as 
angina.50  
 
Risk factors for LVH 
 Given the pathophysiologic complexity of LVH, multiple comorbidities have been 
identified which can play an independent or synergistic role in the phenotype of disease. (Table 
1) However with the inter-related nature of the various comorbidities, the definitive 
proportional contribution can remain elusive. 
Early echo results from the FHS clearly showed a relationship between BP and LVH in a 
large population of patients.51 Devereux et al. conducted a more focused analysis in 1,935 
patients from the Strong Heart study of between 1993 and 1995. They confirmed a relationship 
between both systolic BP(SBP) and diastolic BP(DBP) and LVM, but the correlation was weaker 
than expected (r=.22 and r=0.20 for SBP and DBP, respectively). When other hemodynamic 
factors, such as stroke volume, were considered in the multivariate analysis , they were able to 
increase the hemodynamic prediction of LVM (r=-.51), but ultimately concluded that half of all 
LVM variability was due to non-hemodynamic factors.24 
The role of diabetes mellitus (DM) in LVH was seen in an analysis of 1,950 patients in the 
HypenGEN study, 20% of whom had DM. As expected those with DM had an increased 
incidence of risk factors known to effect LV size. However, even after adjusting for covariates, 
such as body mass index (BMI), SBP, age, and sex, there was still an increased likelihood of LVH 
in DM patients (38% vs. 26%, p=0.03).52 Another large trial of 1,932 patients from the Northern 
Manhattan Study included 23% of patients with DM. Again, even after adjusting for age, 
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gender, BMI, race, coronary artery disease (CAD), and SBP, they still found an increased risk of 
LVH with DM (adjusted OR 1.46, 95% CI 1.13 to 1.88).53 Animal models of isolated DM have not 
been associated with LVH, however, when exposed to similar HTN stimuli, such as AngII, DM 
mice had significantly more LVH when compared with non-DM mice.54 This suggests that it is a 
multi-factorial process, and while single risk factors can be isolated they also need to be viewed 
in aggregate. Indeed, in patients randomized to treatment in the Losartan Intervention For 
Endpoint reduction in hypertension (LIFE) study, reduction of LVH was associated with a 
decreased incidence of new onset DM (Hazard Radio (HR) 0.62, 95% confidence interval (CI) 
0.50 to 0.78).55 Nonetheless, in the same study, losartan was found to be more effective in the 
reduction of LVH in those without DM than those with DM.56 In addition to LVH, DM has also 
been shown to be related to abnormal LV geometry. A recent CV magnetic resonance (CMR) 
evaluation of the Multi-Ethnic Study of Atherosclerosis (MESA) showed that DM was associated 
with concentric remodeling (CR).57 
 Obesity is a well-recognized risk factor for LVH, however, the contribution of obesity and 
relative risk has been somewhat of a moving target as the definition of LVH is indexed to the 
same variable of body mass. De Simone et. al showed in a healthy normotensive population, 
20% of obese individuals would have LVH if their LVM was indexed to an ideal weight BSA.13 By 
definition, metrics of LVM indexed to height alone will have the greatest incidence of LVH in 
this population, and those which include body mass in allometric scaling will downplay its 
significance. Nonetheless across all studies, regardless of measure of index, the relationship 
between obesity and LVH persists. Levy et al. found a 9-fold to 10-fold increase in LVH from 
their leanest to most obese group in 4,976 patients from the FHS.51 Obesity has been 
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associated with an increase in cardiac output and increased total blood volume, which likely 
plays a role in the pathophysiology of this relationship.50,58 Lavie et al. studied a very large 
population of 30,920 patients, including 11,792 patients with obesity (BMI≥30). They found an 
increased incidence of abnormal LV geometry in obese patients indexed to BSA (49% vs. 44%, 
p<0.001), including increased CR (34 vs. 32%), eccentric LVH (7% vs. 6%), and concentric LVH 
(8% vs. 6%), all p<0.0001. Interestingly overall mortality was lower in the obese compared with 
the non-obese population (3.9% vs. 6.5%, p<0.0001), but abnormal LV geometry still portended 
increased mortality in both groups.59 (Figure 1) Other studies have mirrored these results of 
increased frequency of abnormal LV geometry in obesity, but conversely lower mortality.60 A 
recent large study out of Italy in 2017 found a higher incidence of LVH in obesity when 
compared with normal weight individuals (58.5 vs. 21%, p,0.001).61 Interestingly the incidence 
of LVH was considerably higher than Lavie et al. (12%-15%) likely because LVM was indexed to 
m2.7 and not BSA; unfortunately, no mortality data was available. Another recent large study 
from Italy evaluated 4920 patients with treated HTN and no LVH at baseline, and found that 
baseline obesity status predicted development of incident LVH at 48 month follow up.62 
  Following the myriad of known CV complications, smoking is also related with LVH. In 
the large MESA study mentioned previously, of 4,869 patients evaluated by CMR, current 
smokers had an average increase in LVM of 7.7g over non-smokers.23 In the 4,850 patients from 
the Atherosclerosis Risk in the Community (ARIC) study, smokers had a higher prevalence of 
LVH compared with non-smokers (15% vs. 9%, p=0.008). In the ARIC study LVH was indexed by 
BSA, and the relationship remained even after adjusting for co-variates such as BP and CAD. 
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Unique to this study, they were able to demonstrate a linear relationship between pack-years 
of smoking and LVM index.63 
 Obstructive sleep apnea (OSA) and sleep disordered breathing have been associated 
with CVD for many years, LVH being no exclusion. Night-time hypoxia and frequent awakenings 
have been associated with an increase in sympathetic activity and elevated BP. In an analysis of 
patients from the Sleep Heart Health (SHH) study, even after adjusting for BP, DM, smoking, 
alcohol, and CAD, severe sleep apnea was still associated with an increase in LVM index 
compared to those without, adjusted odds ratio 1.78 (95% CI 1.14-2.79).64 A later analysis 
combining some patients from the SHH study and patients from the ARIC study found the 
independent relationship between OSA and LVH only held up in women not men, however, this 
study was observational with additional inclusion criteria.65 
 Chronic kidney disease (CKD) and end stage renal disease are often seen in the setting of 
LVH, and pose another epidemiological challenge as they are intrinsically linked to other risk 
factors, such as HTN and DM. In a study of 1,160 HTN patients in Japan, of whom 40% had CKD 
(glomerular filtration rate (GFR) <60ml/min/1.72m2), multivariate analysis showed CKD to be an 
independent risk factor for LVH (adjusted OR 1.52, 95% CI 1.18-1.96).66 In a recent study of 
young patients (mean age 40+/-4 years) as part of the Coronary Artery Risk Development in 
Young Adults (CARDIA) study, even a mild decrease in renal function (GFR 60-75ml/min/1.72m2) 
was associated with a greater LVM index on follow up.67 
  As discussed, only a fraction of the variability within LVH can be attributable to BP, 
however, an isolated BP reading used for many studies only represents a fraction of the 
hemodynamic load imposed upon the LV.22 Clearly, BP still remains an important risk factor 
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down to the subclinical level, in fact increases in “normal” BP have been associated with 
progressive increases in LVM, suggesting that it is a continuous variable with pre-clinical 
implications.68,69 Some of the variability within the BP contribution to LVH is due to the 
variability within BP itself. In a meta-analysis of 13 studies on “masked HTN,” elevated 
ambulatory BP with normal office readings was associated with a 29% prevalence of LVH 
compared with 9% of normotensive patients (p<0.01).70 Other studies have confirmed this 
closer relationship of ambulatory BP to LVH in comparison with office BP readings.71 This makes 
empiric sense as LVH can be thought of as an averaged product of many continuous variables in 
the 24-hour period. Indeed, LVM correlates to ambulatory BP better than other known target 
organs damaged by HTN, and may serve as a better surrogate marker of cumulative effect.72 
Other subtleties of BP itself are worth noting, BP trends throughout the day have been 
studied, with a typical dip at nighttime and increase during the day. In the Jackson Heart Study 
those with “reverse dipping” sign, that is a relative BP increase at night, had an increased LVM 
index of 8.3+/-2.1g/m2 compared to those with a normal dipping pattern (p<0.001).73 The 
propagation of BP as it moves through the body is affected significantly by vascular stiffness, 
often creating disparities between central and peripheral BP; central BP can now be measured 
peripherally through the extrapolation of an arterial Doppler wave profile.74 A recent meta-
analysis of 12 studies over the past 15 years showed that central BP was more closely related to 
LVM index than peripheral BP (r=0.30 vs. r=0.26, p<0.01).75 This is likely related to central BP 
more accurately reflecting the hemodynamic load experienced by the LV. A recent trial from 
Austria combined both of these concepts and measured 24-hour ambulatory central BP and 
compared these values with office brachial measurements in 289 patients. They found that 
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central ambulatory BP was more closely related to LVH than office peripheral BP (r=0.47 vs. 
r=0.29, p=0.003). 76 
 
LV Geometry 
 LVH was originally thought to exist in two forms: concentric whereby LV walls increased 
in thickness at the expense of internal diameter, and eccentric where LVM was gained by 
progressive dilation of the internal diameter. In 1992 Ganau et al. coined the term “concentric 
remodeling (CR)” when they described a third type of abnormal LV geometry whereby the LV 
walls were increased relative to the internal diameter, but absolute mass did not exceed the 
upper limit of normal.77 Calculation of relative wall thickness (RWT) has not changed since it 
was first described; posterior wall thickness is multiplied by 2 and divided by the end diastolic 
diameter. Ganau et al. used a cutoff of 0.41 to describe the 95th percentile, and the most recent 
ASE/ESCVI guidelines recommend a cutoff of 0.42.10,77 The posterior wall is used preferentially 
to the septum to mitigate the impact of abnormal septal geometry in the normal population.  
 The traditional paradigm was that concentric LVH (with CR as a precursor) was a 
response to increased afterload, and that eccentric LVH was either the result of increased pre-
load states of decompensated concentric LVH. This is now known to be oversimplified as there 
is significant overlap between sub-types, and a single population can develop any of the 
abnormal LV geometries in response to an identical pathophysiologic condition.78 (Figure 2) 
 The prevalence of abnormal LV geometry varies according to the population studied. In 
a large single institution study of 35,602 patients with normal LV ejection fraction (LVEF) 
referred for echocardiography, 46% of people were found to have abnormal LV geometry, 35% 
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with CR, 5% with eccentric LVH, and 6% with concentric LVH.9 (Figure 3) A large meta-analysis 
from 2012 of 30 studies and 37,700 patients found similar rates of LVH in population studies 
(10-19%), but the prevalence rates increased in HTN cohorts (19-48%), and was highest in those 
with severe HTN and CVD (58-77%).79 LV geometry also seems to be affected by age, as a study 
of 9,771 people over the age of 70 found CR in 43%, followed by concentric LVH (8.5%), and 
eccentric LVH (7.4%).8  
 HTN, while universally recognized as a risk factor for LVH, has been variably associated 
with either eccentric or concentric LVH in different studies.9,80,81 This is likely due to differences 
in baseline population characteristics and co-morbidities. These include DM, a frequent 
covariate, which has been associated with CR and concentric LVH.81 Obesity has traditionally 
been associated with eccentric LVH in the high output model, however, even this has been 
challenged as other studies report increased concentric LVH with obesity.59,82 CAD, likely due to 
myocardial damage and remodeling, is associated with eccentric LVH.83 
 There are surprisingly few studies which examine the natural progression of abnormal 
LV geometry. Milani et al. took 3,616 patients with CR at baseline and re-evaluated them at a 
mean follow up time of 2.5 +/- 1.2 years. 45% of these patients had no change, 43% reverted to 
normal geometry, and 12% progressed to LVH.9 In 2014 Lieb et al. analyzed 2,605 patients from 
the FHS and followed them over two screenings for a period of 4 years, demonstrating 
significant fluidity between LV geometries. Of those with normal LV geometry at baseline, 20% 
developed CR, 8% eccentric LVH, and 4% concentric LVH. A large number (53%) of those with 
CR at baseline reverted to normal LV geometry, with 6% and 7% progressing to eccentric and 
concentric LVH, respectively. Concentric LVH did have some regression as well (29%), but a 
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larger number progressed to eccentric LVH (19%) than those with normal LV geometry or CR.84 
(Figure 2) 
 
LVH and Systolic Function 
 Systolic dysfunction is a well-recognized risk factor for mortality and adverse CVD 
events. Studies of LVH variably include and exclude patients with systolic dysfunction, given 
that it is a potential confounder, but the relationship between LVH and systolic dysfunction 
cannot be ignored.9,85 Many of the same risk factors which predispose patients to LVH are also 
risk factors of systolic dysfunction, and LVH itself is a risk factor for systolic dysfunction. The 
Cardiovascular Health Study evaluated 3,042 patients with a baseline normal LVEF, stratified 
them by quartiles of LVM and followed them for a mean of 4.9+/-0.14 years. Those in the 
lowest quartile of LVM had a 4.8% risk of depressed LVEF on follow up, compared with 14.1% in 
the highest quartile (p<0.001).86 These results were independent of the presence of CAD, 
however, there were more CAD events in the group with LVH at baseline compared to those 
without (8.6% vs. 4.6%, p<0.001). CAD was a factor again in another small study from 2004 of 
159 patients with LVH, of whom 18% progressed to depressed LVEF over 4 years. Interim 
myocardial infarction (MI) was the single biggest predictor of depressed LVEF (41% vs. 8%, 
p<0.001).87 In the MESA study of 4,869 patients who had a CMR exam, the presence of CAD was 
not specifically evaluated but patients with a smoking history and DM (both risk factors for 
coronary artery disease) were found to have lower LVEF.23 Milani et al. analyzed 1,024 patients 
with concentric LVH and normal LVEF and followed up at a mean of 33+/-24 months, and found 
that 13% developed systolic dysfunction. The most common variable among those who 
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developed a depressed LVEF was interval MI.85 Krishamoorthy et al. found similar results in a 
population of concentric LVH, with 20% developing depressed LVEF at 7.5 years, again with 
interval MI as the most common risk factor. Interestingly , the most common phenotype among 
those who developed depressed LVEF was still concentric LVH.88 
  
Prognosis   
 Beyond tying together a diverse group of CVD risk factors, the true value in measuring 
LVH is its ability to predict a variety of clinical outcomes. (Table 2) This was studied early in 
3,220 patients from the FHS with echo data, free from CVD at baseline, and followed for 4 
years. Baseline LVM predicted incident CVD, death from CVD, as well as all-cause mortality, 
even after adjusting for age, smoking, obesity, DM, BP, and cholesterol.89  
 Within subtypes of LV geometry, there is disagreement between studies as to which 
pattern is the most predictive of mortality. This is likely due to differences in population 
characteristics between studies. In an early study of a thousand patients from Cook County 
Hospital in Chicago, patients referred for angiogram with an echo were followed for 9 years. 
Patients with concentric LVH were found to have the highest all cause as well as CVD mortality, 
followed by eccentric LVH, and then CR, regardless of CAD status.90 In a larger population of 
older individuals referred for echo for routine clinical indications, Lavie et al. also found 
concentric LVH had the highest rate of mortality on a three year follow up. In contrast to the 
prior study though, they found that CR actually had a slightly higher mortality rate than 
eccentric LVH.59 In a larger study (n=35,602), Milani et al. also found concentric LVH to have the 
highest mortality with less difference between CR and eccentric LVH (10.4%, 8.7%, and 8.4% 
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respectively).9 (Figure 4) When the transition from one subtype of abnormal LV geometry was 
studied, those who progress to frank LVH from CR have universally worse prognosis than those 
who normalize.9,84  
 Two studies out of Italy in the early 2000s showed a continuous relationship between 
LVM and CVD events. The first of 1,925 men with LVM were stratified into quintiles and 
followed for 4 years. They found a continuously increased risk between each quintile, with 
those in the highest quintile having a relative risk (RR) of 3.5 (95% CI 1.8-6.8) for CVD events 
compared with those in the lowest quintile.91 The second study was multi-institutional and 
showed a 40% increase in CVD risk for every 39g/m2 of increase in LVM.92 This continuous 
relationship between LVM and CVD events has been prospectively validated.93 Conversely when 
LV regression has been studied, there was a RR 0.66 (95% CI 0.44-0.88) of CVD events for every 
standard deviation reduction in LVM.94 Despite this strong association with CVD risk, LVH is not 
routinely considered in risk stratification assessments. 95 
 
Stroke and Atrial Fibrillation (AF) 
 LVH was an early recognized risk factor for stroke in the FHS, with an elderly 8 year 
follow up showing an 18.4% incidence of stroke in the highest quartile of LVM index vs. 5.2% in 
the lowest quartile (adjusted HR 2.72, 95% CI 1.39-5.36).96 In a large CMR analysis, LVM was 
weakly correlated with stroke (HR 1.2 per 10% increase in LV mass), but more specifically 
LVM/volume ratio, or concentricity, had a very strong association (HR 4.2 per g/ml mass 
increase).97 What is not known is whether these strokes are related to concomitant vascular 
disease or AF. Verdecchia et al. found that for every standard deviation increase in LVM, the 
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risk of AF was increased by 1.2 (95% CI 1.07-1.34) in a 5 year follow up.98 A 2014 meta-analysis 
of 27,141 patients in 10 studies showed an 11.1% risk of supraventricular tachycardia (including 
AF) in those with LVH vs. 1.1% risk in those without (p<0.001).99 In a recent study from Japan, 
this LVH-AF link was found to be strongest in those with eccentric and concentric LVH, less so in 
CR.100 Accordingly, those with LVH regression by EKG in the LIFE study had a 12% lower rate of 
new onset AF for every standard deviation reduction in Cornell EKG product.101 This decreased 
rate of LVH and new onset AF corresponded with a decreased rate of stroke in the losartan 
treated arm of this study, further solidifying the relationship between changes in LVM, AF, and 
stroke.102  
 
Sudden Cardiac Death (SCD)/Ventricular Ectopic Activity(VEA) 
 One of the mechanisms of CVD mortality associated with LVH is through ventricular 
arrhythmias and SCD. LVH was one of the early identified risk factors of SCD in the FHS, which 
found a 5- to 9- fold increase in SCD among patients with EKG evidence of LVH and 
intraventricular conduction delay. Notably this risk was comparable to those with established 
symptomatic CAD.103 A later echocardiographic analysis from the same study found a linear 
relationship, with an adjusted hazard ratio (HR) of SCD of 1.45 (95% CI 1.22-3.88) for every 
50g/m increase in LVM.104 The pathophysiology of ventricular arrhythmia in LVH has several 
potential mechanisms. Decreased coronary flow reserve in LVH induces subendocardial 
ischemia increasing VEA. Indeed multiple studies have found increased ectopy in LVH.105,106 In 
animal models of LVH, the LV was also more susceptible to fibrillation from programmed 
stimulation. This was found to be related to a dispersion of refractory and repolarization 
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periods with the increase in LVM– effectively increasing the vulnerable periods of the QRS 
cycle.107 The relationship between abnormalities of depolarization and SCD was seen in the LIFE 
study evaluating losartan in HTN patients. In an multivariate risk adjusted analysis, they found 
both baseline QRS duration and QT-peak interval were significantly associated with all-cause 
and CVD-mortality.108 Accordingly, regression of EKG criteria for LVH was associated with a 
reduction in SCD independent of BP in separate studies of both ramipril and losartan.109,110 
Most recently an analysis out of Oregon from the Sudden Unexpected Death Study analyzed all 
types of LV geometry and found increased risk of SCD in concentric LVH, eccentric LVH, and 
even CR (Odds Ratio (OR) 3.20, 2.47, and 1.76 respectively, p<0.007).111  
 
Therapy to Reduce LVH 
 With LVH being easily measurable and closely related to prognosis across a wide variety 
of CVD processes, it has been used extensively as a surrogate marker of treatment benefit. 
(Table 3) The most representative example of this is the LIFE study, which randomized 9193 
people with HTN and LVH to either losartan or atenolol and followed them for a mean time of 
4.8+/- 0.9 years. There was no difference in mean BP at the end of the study, but the losartan 
group showed significant reductions in LVH criteria by EKG, as well as a lower composite 
endpoint of death, stroke, or MI.112 A sub-study of LIFE included 960 patients with echo at 
baseline and yearly through 5 years. Losartan was associated with a significant reduction in 
LVM index independent of BP (-21.7g/m2 vs. -17g/m2, p=0.021).113 This reduction in LVH by 
echo was also associated with a reduction in the composite primary end point (HR 0.78 per -
25g/m2 in mass reduction, 95% CI 0.65-0.94).114 Larger analyses of the study including those 
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with EKG criteria for LVH found a significant relationship between LVH and all of the individual 
outcome criteria: CVD-mortality, MI, stroke, and all-cause mortality.115 Changes in LVH were 
also associated with improved parameters of diastolic function, and decreased recurrent 
hospitalizations for HF.116,117  
A recent study from 2017 involving LVH and losartan found results comparable to that 
of the LIFE study, and studies of different ARBs have shown comparable benefit over beta 
adrenergic blockers.118,119 When used in populations with diabetes and CKD, losartan was 
shown to decrease LVH and improve renal outcomes. Remarkably it was able to decrease CVD 
risk in patients with LVH to levels similar of those without LVH, likely due to the added benefits 
of angiotensin receptor blockade in this population.120 
 Other commonly used anti-hypertensives have been studied, however, none as 
thoroughly as losartan. The Action in Diabetes and Vascular Disease (ADVANCE) study 
evaluated perindopril-indapamide vs. placebo in patients with DM, and found a reduction in 
major adverse CVD events as well as a reduction in LVM index, but it also reduced BP in the 
treatment arm, thus confounding these results.121 When compared with atenolol, perindopril-
indapamide showed improved reduction in LVM index, but also an improved central BP 
reduction over the beta adrenergic-blockers – a theme that is seen in other studies.122 A recent 
study of amlodipine+/-perindopril vs. atenolol+/-bendroflumethiazide found more significant 
reduction in LVM with the former.123 When compared head to head angiotensin converting 
enzyme (ACE) inhibitors have shown no difference in reduction of LVM when compared with 
calcium channel blockers (CCBs).124 A meta-analysis of 80 trials and 3,767 patients found a 
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reduction in LVM index of 13% with ARBs, follow by 11% with CCBs, 10% with ACE inhibitors, 
8% with diuretics, and 6% with b-blockers.125 
 Exercise has consequences on LVM with disparate effects depending on the population 
in which it is studied. In young otherwise healthy individuals, endurance training results in 
increased LVM with concordant increases in LV diameter and improvement of diastolic 
metrics.126 In slightly older individuals, regular physical exercise has been shown to reasonably 
prevent the development of LVH in comparison with sedentary individuals (OR 0.24 CI 0.07-
0.85).127  
 Obesity is a known risk factor for LVH, and can be dramatically improved with bariatric 
surgery. In a longitudinal study of 43 patients having bariatric surgery, LVM index was found to 
decrease by 6.3g/m2.7 at 9 months following surgery.128 A meta-analysis from 2014 of 1,066 
patients undergoing bariatric surgery showed a standardized mean difference of -0.46 in LVM 
index for individuals before and after bariatric surgery (p<0.001).129 
 Other less commonly considered but studied medications in the regression of LVH 
include spironolactone, allopurinol, direct renin inhibitors, and sacubitril/valsartan. With the re-
emergence of spironolactone as a preferred anti-HTN therapy, it has been studied with LVM in 
two recent small studies. Spironolactone was found to decrease LVM, and when studied against 
non-spironolactone therapy, it improved diastolic parameters and reduced the risk of new 
onset symptomatic congestive HF.130,131 Allopurinol inhibits xanthine oxidase, which in addition 
to uric acid metabolism also plays a role in generating reactive oxygen species which contribute 
to myocardial remodeling. In post MI animal studies allopurinol was found to reduce LVH and 
decrease interstitial fibrosis.132 In a small randomized study of patients with CKD, allopurinol 
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was found to significantly reduce LVH (p=0.036).133 In another small randomized study of 66 
patients with CAD, allopurinol was again found to improve LVM after 9 months of therapy.134 
Aliskiren, the direct renin inhibitor, was studied in a randomized trial against losartan, and 
shown to be equally effective at lowering BP as well as decreasing LVM with a similar side effect 
profile.135 Most recently the neprilysin inhibitor/ARB combination, sacubitril/valsartan, was 
studied against olmesartan in a randomized trial of 114 patients over 52 weeks. Despite a 
modest decrease in SBP, but not DBP, in the sacubitril/valsartan arm, they did find significant 
reductions in LVM index (-6.83 vs. -3.55 g/m2, p<0.029).136 In contrast to these positive results, 
recent studies of alternative therapies such as renal denervation or long acting nitrates have 
shown no benefit in the reduction of LVH.137,138  
 
Conclusion 
 LVH has been one of the most well studied clinical variables over the past 50 years of 
CVD research. As a measurable outcome, it exists both as a metric of the combined influence of 
many external and internal factors, as well as a prognostic marker for events to come. It is 
diverse in its phenotypes along a continuum of concentricity and LV dilation. LVH has been used 
as a surrogate marker of therapeutic success while awaiting clinical results, and a hard endpoint 
for individualized therapy. Despite its ubiquity, it is not routinely used in risk stratification, and 
the clinical implication when measured on echo often goes overlooked. Through a greater 
understanding of their significance, abnormal LV geometry and LVH can be included more often 
in the routine assessment of CVD. 
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Table 1. Risk factors for LVH 
 Hypertension 
 Diabetes mellitus 
 Obesity 
 Obstructive sleep apnea 
 Chronic kidney disease 
 Tobacco use 
 Sodium Intake 
 
 
Table 2. LVH prognostic associations 
 All-cause mortality 
 Atrial fibrillation 
 Congestive heart failure 
 Diastolic dysfunction 
 Myocardial infarction 
 Reduced coronary flow reserve 
 Stroke 
 Sudden cardiac death 
 Ventricular ectopic activity 
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Table 3. Therapy shown to reduce LVH 
 Angiotensin converting enzyme 
inhibitors 
 Angiotensin receptor blockers 
 Aldosterone receptor antagonist 
 Allopurinol 
 Calcium channel blockers 
 Direct renin inhibitors 
 Exercise 
 Sacubitril/valsartan 
 Weight reduction 
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Figure 1. Mortality by left ventricular geometry in 11,792 obese patients with preserved 
ejection fraction followed for 3.2+/-1.4 years. Concentric remodeling (CR), eccentric 
hypertrophy (EH), concentric hypertrophy (CH). (reproduced with permission from Lavie et 
al.59) 
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Figure 2. Adverse left ventricular (LV) remodeling includes concentric remodeling (increased 
relative wall thickness (RWT) without increase in LV mass), eccentric hypertrophy (increase LV 
mass without increased RWT), and concentric hypertrophy (increase in LV mass as well as 
increased RWT).  The progression between subtypes is more fluid that once thought and a 
transition between any two types of abnormal LV geometry is possible. (images adapted with 
permission from Patrick J. Lynch, medical illustrator; C. Carl Jaffe MD, cardiologist. Creative 
Commons Attribution 2.5 License 2006) 
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Figure 3. Frequency of left ventricular (LV) geometry subtype in a population of 35,602 patients 
with normal LV ejection fraction.  (reproduced with permission from Milani et al.9)  
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Figure 4. Plot of cumulative hazard over time for survival stratified by left ventricular geometry. 
A. Normal structure, concentric remodeling (CR), and left ventricular hypertrophy (LVH). B. 
Concentric hypertrophy (CH), CR, eccentric hypertrophy (EH), and normal structure. 
(reproduced with permission from Milani et al.9) 
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